Charles River Laboratories International, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in Q3 of fiscal 2026, the quarter ended Sep 26, 2026 was Discovery And Safety Assessment at $596.3 million, 61% of the total. By sales mix, the largest line in Q3 of fiscal 2026, the quarter ended Sep 26, 2026 was Services at $780.3 million, 79% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 26, 2026
|
Q3 FY2026
Sep 26, 2026
|
Q2 FY2026
Jun 27, 2026
|
Q1 FY2026
Mar 28, 2026
|
Q4 FY2025
Dec 27, 2025
|
Q3 FY2025
Sep 27, 2025
|
Q2 FY2025
Jun 28, 2025
|
Q1 FY2025
Mar 29, 2025
|
Q4 FY2024
Dec 28, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3,977
|
983
|
1,004
|
996
|
994
|
1,005
|
1,032
|
984
|
1,003
|
| Operating segments | |||||||||
| Discovery And Safety Assessment |
2,391
-1.0%
share 60.1%
|
596
-0.7%
share 60.7%
|
607
-1.9%
share 60.4%
|
597
+0.7%
share 59.9%
|
592
-2.0%
share 59.5%
|
601
share 59.8%
|
618
share 59.9%
|
593
share 60.2%
|
603
share 60.2%
|
| Research Models And Services |
832
-1.5%
share 20.9%
|
208
-2.8%
share 21.1%
|
209
-1.8%
share 20.9%
|
208
-2.2%
share 20.9%
|
206
+1.0%
share 20.7%
|
213
share 21.2%
|
213
share 20.7%
|
213
share 21.7%
|
204
share 20.4%
|
| Manufacturing Support |
754
-1.4%
share 19.0%
|
179
-6.2%
share 18.2%
|
188
-6.3%
share 18.7%
|
191
+6.8%
share 19.1%
|
196
+0.7%
share 19.8%
|
191
share 19.0%
|
201
share 19.5%
|
178
share 18.1%
|
195
share 19.4%
|
| Sales mix | |||||||||
| Services |
3,190
-2.1%
share 80.2%
|
780
-3.4%
share 79.4%
|
808
-3.9%
share 80.5%
|
798
+0.0%
share 80.1%
|
803
-1.1%
share 80.8%
|
808
share 80.4%
|
841
share 81.5%
|
798
share 81.1%
|
812
share 81.0%
|
| Product |
787
+2.8%
share 19.8%
|
202
+2.8%
share 20.6%
|
196
+2.3%
share 19.5%
|
198
+6.1%
share 19.9%
|
191
+0.2%
share 19.2%
|
197
share 19.6%
|
191
share 18.5%
|
186
share 18.9%
|
191
share 19.0%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- CRL (NYSE)
- Fiscal year ends
- December 27
- Headquarters
- Wilmington, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1100682
- Former names
- CHARLES RIVER LABORATORIES INTERNATIONAL INC (until May 30, 2019); CHARLES RIVER LABORATORIES HOLDINGS INC (until Jan 28, 2000)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.